The trial will enrol a total of 132 subjects in the US, Argentina, and Brazil. Credit: Mark Fletcher-Brown on Unsplash.

BioAge Labs has initiated a Phase II clinical trial of a potent oral inhibitor of prostaglandin D2 (PGD2) DP1 signalling, BGE-175, for treating Covid-19 patients aged 60 years and above.

DP1 signalling is linked to high chances of infection and an increased risk of mortality from the infectious disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In various Phase I–III clinical trials for allergic rhinitis carried out by Shionogi & Co, BGE-175 showed to be safe and well-tolerated in more than 2,400 study subjects.

The randomised, placebo-controlled, parallel-group, multi-centre, double-blind Phase II study will have elderly subjects hospitalised for Covid-19 without respiratory failure.

It will enrol a total of 132 subjects in the US, Argentina, and Brazil. They will be given daily doses of BGE-175 or placebo (66 in each group) for up to 14 days.

Patients will receive the study medication orally while patients unable to swallow will receive it through a nasogastric tube.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The percentage of patients who die or develop respiratory failure within 28 days of receiving the first dose of BGE-175 will form the trial’s primary endpoint.

Viral load, clinical improvement or worsening, incidence and duration of supplementary oxygen or ventilation, time to discharge or rehospitalisation ICU admission, in 57 days after the first dose, will be the secondary endpoints.

Furthermore, PGD2 DP1 signalling activity and the levels of inflammatory markers will be studied.

BioAge CEO Kristen Fortney said: “By reversing age-related dysregulation of critical immune mechanisms, BGE-175 could allow older patients to more effectively fight off Covid-19.

“Our strongly encouraging preclinical data show that BGE-175 almost completely protects older mice against lethality from infection with SARS-CoV-2, the virus that causes Covid-19.

“In addition, BGE-175 dramatically decreases viral load in lung tissue, which is correlated with both disease severity and transmission of the virus.”

The company anticipates top-line results this year.